Hyperhomocysteinemia Prevalence Among Patients With Venous Thromboembolism

Department of Pulmonary Medicine, Gazi University School of Medicine, Besevler, Ankara, Turkey.
Clinical and Applied Thrombosis/Hemostasis (Impact Factor: 2.39). 10/2011; 17(5):487-93. DOI: 10.1177/1076029610378499
Source: PubMed

ABSTRACT The aim of this study is to evaluate the plasma total homocysteine level in patients with venous thromboembolism (VTE) and to investigate the effect of different risk factors on plasma levels. Ninety-three-patients with VTE and 37-control participants diagnosed with other than VTE were included in the study. Plasma homocysteine levels and the factors affecting plasma homocysteine levels were evaluated. Plasma homocysteine level was higher among patients with VTE compared to the controls independent from vitamin B12 and folate levels. The prevalence of hyperhomocysteinemia in VTE was 63%. Plasma homocysteine level was higher in patients with PE than deep venous thrombosis (DVT; 23 ± 13.7 vs 16 ± 5.8 μmol/L, P = .018). With regression analysis hyperhomocysteinemia was found to be associated with a 4.8-fold increased risk of VTE. Hyperhomocysteinemia is a common and possibly modifiable risk factor that should be considered when screening patients with VTE. Secondary causes of hyperhomocysteinemia especially vitamin B12 deficiency should be monitored in patients with VTE to prevent recurrences.

Download full-text


Available from: Neslihan Celik Bukan, Mar 06, 2015
1 Follower
18 Reads
  • Source
    • "Hyperhomocysteinemia has been well-documented to increase the risk of arterial thrombotic events, including myocardial infarction [4], stroke [5] and peripheral arterial disease [6]. Data concerning venous thrombosis also point to an increased risk for hyperhomocysteinemia [3,7-9]. In one case–control study, researchers found an increased risk for venous thromboembolism associated with reduced vitamin B12, together with increased methylmalonic acid levels, in the presence of hyperhomocysteinemia [10]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Acute portomesenteric vein thrombosis is an uncommon but serious condition with potential sequelae, such as small-bowel gangrene and end-stage hepatic failure. It is known to be caused by various pro-thrombotic states, including hyperhomocysteinemia. We describe what is, to the best of our knowledge, the first reported case of concomitant thrombosis of portal, superior mesenteric and splenic veins due to hyperhomocysteinemia secondary to pernicious anemia and no other risk factors. Case presentation A 60-year-old Indian man presented with epigastric pain, diarrhea and vomiting. An abdominal imaging scan showed that he had concomitant pernicious anemia and concomitant portal, superior mesenteric and splenic vein thrombosis. A work-up for the patient’s hypercoagulable state revealed hyperhomocysteinemia, an undetectable vitamin B12 level and pernicious anemia with no other thrombophilic state. He developed infarction with perforation of the small bowel and subsequent septic shock with multi-organ dysfunction syndrome, and he ultimately died due to progressive hepatic failure. Conclusion This report demonstrates that pernicious anemia, on its own, can lead to hyperhomocysteinemia significant enough to lead to lethal multiple splanchnic vein thrombosis. Our case also underscores the need to (1) consider portomesenteric thrombosis in the differential diagnosis of epigastric abdominal pain, (2) perform a complete thrombotic work-up to elucidate metabolic abnormalities that could be contributing to a pro-thrombotic state and (3) initiate aggressive measures, including early consideration of multi-visceral transplantation, in order to avoid decompensation and a significant adverse outcome.
    Journal of Medical Case Reports 08/2014; 8(1):286. DOI:10.1186/1752-1947-8-286
  • [Show abstract] [Hide abstract]
    ABSTRACT: The estimation of mobile terminal position using received signal strength measurements has been considered for cellular systems in the past. An evaluation of the potential performance of such location estimation methods is of interest. The widely used Cramer-Rao bound is not well suited for this purpose due to discontinuities or large variations in the function describing the relationship between received signal strength and the corresponding position of the mobile terminal. In this paper, the Barankin bound is used to alleviate this problem. A method for determining the lower bounds for any coverage area of interest is described. Lower bounds are presented for a candidate area based on field measurements of received signal strengths.
    Vehicular Technology Conference, 2004. VTC 2004-Spring. 2004 IEEE 59th; 06/2004
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Microparticles (MPs) are small membrane vesicles released by stimulated or apoptotic cells, including the endothelium. Hyperhomocysteinemia (HHcy) is a blood disorder characterized by an increase in the plasma concentrations of total homocysteine (Hcy). The plasma Hcy level is determined by environmental factors (dietary habits, i.e. the intake of folic acid, FA) and genetic factors (N (5),N (10)-methylenetetrahydro-folate reductase, MTHFR, polymorphism 677C>T). To evaluate whether moderate Hcy concentrations induce endothelial MP formation, the role of FA supplementation and the influence of MTHFR polymorphism were analysed. Human umbilical vein endothelial cells (HUVEC) were treated in vitro with 50 μM of Hcy and methionine (Met). The MP number and apoptotic phenotype were analyzed using flow cytometry. Increasing doses of FA (5, 15 and 50 μM) were used to reduce the HHcy effect. The MTHFR 677C>T polymorphism was determined. HUVEC stimulated by Hcy produced significantly more MPs than HUVEC under the control conditions: 3,551 ± 620 vs 2,270 ± 657 kMP (p = 0.02). Supplementation with FA at concentrations of 5, 15 and 50 μM reduced the MP count in the cell culture supernatant to 345 ± 332, 873 ± 329, and 688 ± 453 kMP, respectively (p = 0.03). MTHFR 677C>T heterozygosity was associated with a significant increase in MP formation after stimulation with Hcy compared to the control conditions: 3,617 ± 152 vs 1,518 ± 343 kMP (p = 0.02). Furthermore, the MTHFR genotype altered MP formation after Met loading. On average, 24% of the entire MP population was apoptotic (annexin V-positive). Endothelial function impairment due to HHcy is related to MP shedding, which may involve platelets and other blood and vascular cells. MP shedding is a physiological response to moderate HHcy.
    Cellular & Molecular Biology Letters 03/2011; 16(1):69-78. DOI:10.2478/s11658-010-0040-2 · 1.59 Impact Factor
Show more